Bristol Drug Seen Helping Body Attack Deadly Lung Cancer

Bristol Drug Seen Helping Body Attack Deadly Lung Cancer

Christopher Barth/Bloomberg

The Bristol-Myers Squibb offices in Lawrence, New Jersey. In an initial trial of 240 patients, the Bristol-Myers drug, known as BMS-936558 , shrunk tumors in 24 of 95 melanoma patients, 10 of 33 people with kidney cancer and 13 of 75 of those with advanced lung cancer, according to preliminary information on the data, gathered in the first phase of tests usually needed for regulatory approval.